Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Manufacturing Engineered and Refractory AAV Capsids for In Vivo Research

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Manufacturing Engineered and Refractory AAV Capsids for In Vivo Research

CELL & GENE | RNA | BIOLOGICS

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Proven Intelligence in AAV Vector Engineering and Production.

Executive Summary

The production of engineered or refractory AAV capsids presents unique challenges not encountered with common, well-characterized serotypes. These vectors, designed for enhanced tissue tropism or immune evasion, often have lower production yields, aggregation, and complex purification profiles. Manufacturing these advanced vectors for in vivo research requires bespoke process development and advanced analytical characterization to ensure the generation of high-quality material suitable for IND-enabling studies.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

Frequently Asked Questions

What are the primary manufacturing challenges associated with novel or engineered AAV capsids compared to common serotypes like AAV9?

Engineered AAV capsids frequently exhibit lower production titers, a higher propensity for aggregation, and altered purification characteristics in standard iodixanol or chromatography systems. Overcoming these issues requires custom process development, including optimization of transfection conditions and the implementation of bespoke purification strategies and analytical assays to ensure vector integrity and purity for in vivo applications.

How does the quality of a research-grade AAV vector for a refractory capsid impact the timeline for IND-enabling toxicology studies?

The quality of the initial research vector directly influences the reliability of early in vivo data. A poorly characterized or impure vector can generate confounding results, leading to program delays. High-quality vectors with well-defined key quality attributes (KQAs) from the outset provide a clear data package, streamlining the path toward formal IND-enabling toxicology studies and supporting an 18-24 month timeline to IND.

What is the process for transitioning a novel AAV vector from research-grade production to a GxP-compliant manufacturing pathway?

The transition involves a comprehensive technology transfer process. Key steps include locking down the plasmid production process, adapting the upstream cell culture and transfection methods for larger scale, and developing scalable downstream purification protocols. Most importantly, analytical methods used for research-grade characterization must be qualified and validated to meet GxP standards for identity, purity, and potency.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Addressing the Complexity of Novel AAV Vector Production

Standard AAV serotypes rely on established, high-yield production and purification protocols. Engineered capsids, however, disrupt this paradigm. Modifications to the capsid surface, intended to alter tropism or reduce immunogenicity, can interfere with particle assembly, stability, and interactions with purification resins. This necessitates a scientifically-driven approach to process development that moves beyond template-based procedures.

Our approach is built on a deep understanding of AAV biology. Vector performance is a function of receptor availability on target cells and post-transduction cellular processes. We leverage insights into receptor biology to inform capsid selection and strategies that maximize in vivo transduction efficiency (PMID: 21576824). Similarly, our vector design considers downstream biological pathways, including cellular mechanisms that can be modulated to enhance transgene expression after the vector has reached its target (PMID: 15771962).

Expertise Forged Over Decades

The scientific team at Franklin Biolabs has a long history of successfully producing thousands of distinct vectors, including many novel and difficult-to-express capsids. This expertise was developed over years as part of the Penn Vector Core before the team transitioned to Franklin Biolabs.

This continuity ensures that programs developing next-generation therapies have access to an unparalleled knowledge base for troubleshooting and optimizing the production of their unique vectors. For a detailed overview of initiating AAV programs, from capsid engineering to preclinical profiling, see our discussion here:.

Foundational Quality for Global Submissions

A high-quality research vector is the foundation of a successful therapeutic program. By resolving production and purification challenges early, we generate material that produces clean, interpretable data in foundational in vivo studies. This rigor underpins the 100% successful IND rate achieved by our core scientific leadership since 2019, established prior to the formal launch of Franklin Biolabs in 2024.

Our process is designed with global regulatory expectations in mind, aligning with ICH guidelines to facilitate comprehensive IND and IMPD submissions for our clients. This foundational work is a component of our broader AAV Research Vector Packaging Services.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

SVG Diagram: AAV Production Approach Comparison

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities